PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

TG Therapeutics grabs FDA approval for MS drug

TG Therapeutics announced the U.S. FDA has approved its monoclonal antibody for the treatment of relapsing forms of multiple sclerosis (RMS), providing patients with a new treatment option.

The approval includes use in adult patients with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The drug, which will be marketed as Briumvi, is the first and only anti-CD20 monoclonal antibody approved for patients with RMS that can be administered in a one-hour infusion following the starting dose. It will join other marketed treatments for relapsing MS, including Novartis’ Kesimpta and Roche’s Ocrevus, giving people with MS another choice of treatment.

The approval is good news for New York-based TG Therapeutics after the FDA withdrew approval of TG’s cancer drug Ukoniq earlier this year when an ongoing trial continued to report a possible increased risk of death in patients receiving the treatment.

Approval for Briumvi was granted based on data from the ULTIMATE I & II phase 3 trials. TG Therapeutics said it expects to launch the drug in the first quarter of 2023.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026